Aclaris Therapeutics (ACRS) Research & Development (2014 - 2026)

Aclaris Therapeutics' Research & Development history runs 13 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• On a quarterly basis, Research & Development rose 35.16% year-over-year to $15.7 million in Q1 2026; TTM through Mar 2026 was $56.7 million, a 60.56% increase from a year earlier, with the FY2025 full-year figure at $52.6 million, up 56.75% from the prior year.
• Research & Development eased to $15.7 million in Q1 2026 per ACRS's latest filing, from $16.6 million in the prior quarter.
• Across five years, Research & Development topped out at $26.6 million in Q4 2023 and bottomed at $6.0 million in Q3 2024.
• The 5-year median for Research & Development is $15.7 million (2026), against an average of $16.4 million.
• Across the five-year window, Research & Development surged 137.8% in 2022 and tumbled 75.05% in 2024, its largest moves.
• Year by year, Research & Development stood at $21.1 million in 2022, then grew by 26.45% to $26.6 million in 2023, then tumbled by 66.13% to $9.0 million in 2024, then soared by 83.74% to $16.6 million in 2025, then decreased by 5.59% to $15.7 million in 2026.
• Per Business Quant, the three latest ACRS Research & Development figures stand at $15.7 million (Q1 2026), $16.6 million (Q4 2025), and $13.0 million (Q3 2025).